Home > Insider Trading > Filing (0000899243-16-014985)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
907654	Arca Biopharma Inc.	ABIO	In Vitro & In Vivo Diagnostic Substances (2835)	363855489

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1266125	R Michael Bristow	Arca Biopharma, Inc. 11080 Circlepoint Road, Suite 140 Westminster CO 80020	See Remarks	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-03-01	752	$3.50	45,334	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	19,986	Indirect	By Investocor Trust as sole Trustee
Common Stock	25,459	Indirect	By NFS Custodian for Michael Bristow's IRA

Footnotes

Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (iii) 6,871 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 28,461 previously reported shares of common stock held directly.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $3.50 to $3.53. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.